No definition available.
Squamous cell neoplasms and carcinoma of cervix, excluding all cancers (controls excluding all cancers)
C3_CERVIX_SQUAM_EXALLC
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleonly females |
293373 |
2. Check conditionsNone |
293373 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
232 |
4. Check minimum number of eventsNone |
232 |
5. Include endpointsNone |
232 |
6. Filter based on genotype QC (FinnGen only) |
232 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Squamous cell neoplasms and carcinoma of cervix, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Squamous cell neoplasms and carcinoma of cervix
- Malignant neoplasm of cervix uteri
- Malignant neoplasm of cervix uteri, excluding all cancers (controls excluding all cancers)
- malignant neoplasm of female genital organs
- malignant neoplasm of female genital organs, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 232 | 232 | - |
| Unadjusted period prevalence (%) | 0.08 | 0.08 | - |
| Median age at first event (years) | 43.06 | 43.06 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 225
- Matched controls
- 2250
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8070/3-C53.9
ICD-O-3
Squamous cell carcinoma, NOS, of cervix uteri
+∞
204.8
164
*
C53.11
ICD-10 Finland
Squamous cell carcinoma and exocervix
+∞
128.9
111
*
C53.01
ICD-10 Finland
Squamous cell carcinoma of the endocervix
+∞
109.6
96
*
128
Kela drug reimbursment
Cancers of female genital organs
+∞
77.7
70
*
ULA02
NOMESCO Finland
Kolposcopy
10.9
48.8
109
178
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
9.6
45.8
112
210
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
45.4
42
*
LDA20
NOMESCO Finland
Biopsy of vaginal cervix
11.8
43.2
88
116
LDC03
NOMESCO Finland
Conisation of cervix uteri using diathermy or laser
16.1
42.9
73
65
WF002
NOMESCO Finland
Radical radiotherapy
478.9
41.5
40
*
H02AB02
ATC
dexamethasone; systemic
51.7
41.4
49
12
R87.6
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal cytological findings
9.1
39.7
96
169
LCD30
NOMESCO Finland
Radical hysterectomy
+∞
37.6
35
*
8070/3-C53.1
ICD-O-3
Squamous cell carcinoma, NOS, of exocervix
+∞
36.4
34
*
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
+∞
34.2
32
*
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
87.8
34.0
37
5
A04AA55
ATC
palonosetron, combinations; systemic
+∞
32.0
30
*
ZX020
NOMESCO Finland
HDR radiotherapy within tissue
+∞
30.9
29
*
LCD31
NOMESCO Finland
Radical laparoscopic hysterectomy
+∞
29.9
28
*
ZX040
NOMESCO Finland
Intracavity HDR radiotherapy
+∞
29.9
28
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
28.8
27
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
28.8
27
*
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
165.6
28.4
29
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
27.7
26
*
A04AA01
ATC
ondansetron; systemic, rectal
19.2
26.1
40
25
B01AB10
ATC
tinzaparin; parenteral
14.1
25.3
44
38
121
Kela drug reimbursment
Severe hypofunction of sexual glands
24.8
24.3
34
16
WF003
NOMESCO Finland
Adjuvant radiotherapy
267.3
24.1
24
*
ZXC96
NOMESCO Finland
Robot assisted procedure
38.2
24.0
30
9
A03FA01
ATC
metoclopramide; systemic, rectal
5.7
23.6
78
191
8070/3-C53.0
ICD-O-3
Squamous cell carcinoma, NOS, of endocervix
+∞
23.3
22
*
JN4BD
NOMESCO Finland
Extensive body CT
14.1
23.1
40
34
PJA12
NOMESCO Finland
Sentinel node biopsy
254.9
23.1
23
*
C53.00
ICD-10 Finland
Malignant tumor of endocervix without histology
+∞
22.3
21
*
ZX095
NOMESCO Finland
Combined chemoradiotherapy
+∞
22.3
21
*
XX3DW
NOMESCO Finland
Time consuming IT work
11.5
22.0
42
44
PJD54
NOMESCO Finland
Block dissection of iliac lymph nodes
+∞
20.1
19
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
20.1
19
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
20.1
19
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
20.1
19
*
A04AA02
ATC
granisetron; systemic, transdermal
206.5
18.8
19
*
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
13.1
18.7
33
29
LDA10
NOMESCO Finland
Curettage of cervix uteri
8.4
18.5
42
60
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
17.9
17
*
JN2BG
NOMESCO Finland
MRI examination of lower part of abdoment with high intensity magnet
68.8
17.0
19
*
A04AD12
ATC
aprepitant; systemic
+∞
16.9
16
*
Z51.5
ICD-10 Finland
Palliative care
19.0
16.0
24
14
C53.81
ICD-10 Finland
Overall squamous cell carcinoma of the cervix uteri
+∞
15.8
15
*
C53.10
ICD-10 Finland
Malignant tumor of the exocervix without histology
+∞
15.8
15
*
18099
ICD-8 Finland
Malignant neoplasm of cervix uteri
+∞
15.8
15
*
L03AA13
ATC
pegfilgrastim; parenteral
+∞
15.8
15
*
LEB00
NOMESCO Finland
Biopsy of vagina
20.1
15.0
22
12
PJA01
NOMESCO Finland
Laparoscopic sentinel node excision
+∞
14.7
14
*
PJ5AQ
NOMESCO Finland
Sentinell lymphnode SPECT with low dose CT
+∞
14.7
14
*
8310
FHL
Radical hysterectomy (includes lymph node removal)
+∞
14.7
14
*
C53.91
ICD-10 Finland
Squamous cell carcinoma in an unspecified location in the cervix
+∞
14.7
14
*
C53.1
ICD-10 Finland
Malignant neoplasm: Exocervix
+∞
14.7
14
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.4
14.1
87
356
N87.2
ICD-10 Finland
Severe cervical dysplasia, not elsewhere classified
9.3
14.0
29
35
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
+∞
13.7
13
*
C53.0
ICD-10 Finland
Malignant neoplasm: Endocervix
+∞
13.7
13
*
JN5JS
NOMESCO Finland
Extensive PET-MRI of body metabolism
+∞
13.7
13
*
WZC30
NOMESCO Finland
Teaching
6.3
13.6
37
68
JN4KR
NOMESCO Finland
Whole body very extensive metabolic PET with CT
148.6
13.6
14
*
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
27.8
13.6
18
7
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
4.0
13.5
60
188
ZX070
NOMESCO Finland
Intensity modified radiotherapy
74.2
12.7
14
*
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
2.9
12.6
114
594
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
12.6
12
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
12.6
12
*
L03AA02
ATC
filgrastim; parenteral
+∞
12.6
12
*
1801A
ICD-9 Finland
Malignant neoplasm of cervix uteri, Exocervix
+∞
12.6
12
*
B01AB05
ATC
enoxaparin; parenteral
3.0
11.6
83
365
1800A
ICD-9 Finland
Malignant neoplasm of cervix uteri, Endocervix
+∞
11.6
11
*
C53.90
ICD-10 Finland
Malignant tumor in unspecified localization in cervix uteri without histology
+∞
11.6
11
*
PJ5AN
NOMESCO Finland
Localisation of sentinell lymphnode with isotope imaging
+∞
11.6
11
*
C53
ICD-10 Finland
Malignant neoplasm of cervix uteri
+∞
11.6
11
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
126.2
11.5
12
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
126.2
11.5
12
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
126.2
11.5
12
*
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
21.4
11.3
16
8
N02AA05
ATC
oxycodone; systemic
4.2
11.1
44
123
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
115.2
10.5
11
*
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
+∞
10.5
10
*
LAG11
NOMESCO Finland
Laparoscopic oophoropexy
+∞
10.5
10
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
9.4
10.0
20
23
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
104.2
9.5
10
*
Z08.7
ICD-10 Finland
Follow-up examination after combined treatment for malignant neoplasm
+∞
9.4
9
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
9.4
9
*
I89.0
ICD-10 Finland
Lymphoedema, not elsewhere classified
+∞
9.4
9
*
UKC02
NOMESCO Finland
Cystoscopy
4.2
9.3
36
98
ZX120
NOMESCO Finland
Intravenous
4.9
8.9
29
66
WW500
NOMESCO Finland
Blood transfusion
7.5
8.8
20
29
115
Kela drug reimbursment
Breast cancer
+∞
8.4
8
*
YX9VG
NOMESCO Finland
Other MRI eamination with high intensity magnet for dose design of radiotherapy
+∞
8.4
8
*
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
+∞
8.4
8
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
8.4
8
*
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
8.4
8
*
C53.99
ICD-10 Finland
Malignant tumor in unspecified localization in cervix, unspecified histology
+∞
8.4
8
*
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
+∞
8.4
8
*
LBE20
NOMESCO Finland
Laparoscopic bilateral salpingectomy
10.6
7.6
14
14
D06.0
ICD-10 Finland
Carcinoma in situ: Endocervix
26.0
7.6
10
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
7.3
7
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
7.3
7
*
N93.9
ICD-10 Finland
Abnormal uterine and vaginal bleeding, unspecified
7.1
6.9
16
24
N95.0
ICD-10 Finland
Postmenopausal bleeding
3.9
6.9
28
80
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
5.5
6.8
19
37
JN4AD
NOMESCO Finland
Body CT examination
8.2
6.7
14
18
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.9
6.6
26
73
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.6
6.3
48
212
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
6.6
6.3
15
24
18011
ICD-8 Finland
NA
+∞
6.3
6
*
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
+∞
6.3
6
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
6.3
6
*
JN5KS
NOMESCO Finland
Very extensive PET-MRI of body metabolism
+∞
6.3
6
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
6.3
6
*
130
Kela drug reimbursment
Malignant tumour
+∞
6.3
6
*
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
7.6
6.0
13
18
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
39
94
4.79
15.55
2.1
1.5
—
—
—
0
0
100
467
3.01
14.71
2.4
1.5
—
—
—
0
0
112
624
2.54
10.91
6.5
3.3
33.4
36.4
g/l
4.40
104
572
102
556
2.49
10.27
4.5
3.0
—
—
—
0
0
127
775
2.41
9.84
6.4
3.5
—
—
—
0
0
31
97
3.53
8.57
2.0
1.4
—
—
—
0
0
10
6
17.32
6.80
1.0
1.5
—
—
—
0
0
10
14
7.42
6.75
2.6
1.8
—
—
—
0
0
65
366
2.08
5.49
3.9
1.8
—
—
—
0
0
129
923
1.90
5.37
15.2
6.4
4.1
4.1
e9/l
0.03
121
800
112
776
1.86
5.06
8.8
4.5
1.2
1.2
mmol/l
1.57
91
675
45
235
2.14
4.57
4.1
2.6
5.4
3.8
e6/l
0.25
28
115
69
430
1.86
4.23
4.0
2.9
0.6
0.5
e6/l
0.25
57
318
126
944
1.73
4.09
5.2
3.5
6.6
6.5
mmol/l
0.23
120
854
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
11
28
4.07
4.02
1.9
2.8
0.4
0.4
u/ml
—
5
21
13
39
3.47
3.82
1.8
1.1
—
—
—
0
0
82
553
1.75
3.82
4.9
1.9
2.3
2.4
mmol/l
0.59
76
474
30
146
2.21
3.61
3.7
3.0
—
—
—
0
0
13
42
3.22
3.42
2.1
1.6
4.8
1.2
ug/l
0.65
13
36
45
262
1.89
3.35
3.9
2.4
1.6
1.2
e6/l
0.28
27
143
156
1793
0.60
3.10
3.7
4.0
4.9
4.8
mmol/l
0.47
151
1675
115
884
1.60
3.08
6.3
4.9
0.0
0.0
estimate
0.00
15
151
30
156
2.06
3.07
11.5
4.1
1.0
1.0
mmol/l
0.07
30
137
94
691
1.61
3.02
6.6
4.2
1.2
1.2
mmol/l
1.36
89
621
146
1191
1.61
3.02
6.9
4.5
3094.0
3256.3
e6/l
—
6
19
5
5
10.18
2.99
1.8
1.0
—
—
—
0
0
5
5
10.18
2.99
1.8
1.0
—
—
—
0
0
115
890
1.58
2.95
4.4
3.5
0.0
0.0
estimate
0.50
15
153
6
9
6.81
2.88
1.2
1.7
13.8
108.4
u/ml
—
6
9
78
554
1.61
2.86
3.8
2.5
33.3
29.9
u/l
0.25
73
528
156
1780
0.62
2.77
3.7
4.0
1.5
1.6
mmol/l
1.04
150
1657
16
71
2.35
2.40
1.6
1.7
—
—
—
0
0
163
1825
0.64
2.37
3.9
4.5
2.9
2.9
mmol/l
0.11
153
1693
17
80
2.21
2.25
4.9
2.8
0.2
0.2
e6/l
0.05
17
72
151
1709
0.67
2.19
3.4
3.6
1.4
1.2
mmol/l
1.65
144
1578
16
77
2.16
2.02
2.1
1.5
—
—
—
0
0
13
57
2.36
2.01
2.4
1.6
—
—
—
0
0
186
1671
1.57
2.01
21.0
9.2
80.1
83.2
ml/min/173m2
0.98
162
1316
7
21
3.40
1.98
1.1
1.1
—
—
—
0
0
9
34
2.71
1.88
1.6
1.1
—
—
—
0
0
12
53
2.33
1.84
1.9
1.6
—
—
—
0
0
22
124
1.86
1.83
8.4
5.4
10.6
11.6
kpa
0.50
22
119
22
124
1.86
1.83
8.4
5.4
5.1
5.2
kpa
0.22
22
119
13
62
2.16
1.69
3.8
3.2
47.3
44.5
%
0.12
13
62
33
483
0.63
1.67
2.1
1.6
1.7
1.4
mmol/l
1.37
25
419
8
32
2.55
1.61
2.0
3.6
22.7
23.9
mmol/l
—
8
27
6
20
3.05
1.59
1.0
1.5
—
—
—
0
0
31
203
1.61
1.56
2.2
1.7
28.4
29.2
s
0.60
31
198
9
180
0.48
1.47
1.3
1.7
381.7
371.5
nmol/l
—
9
166
17
97
1.81
1.39
2.5
2.1
194.6
4306.6
u/l
—
10
39
32
220
1.53
1.32
2.0
1.7
—
—
—
0
0
195
1816
1.46
1.31
22.9
10.6
28.5
18.5
mg/l
3.39
170
1344
164
1779
0.73
1.30
4.4
4.1
6.0
5.8
mmol/l
1.02
153
1632
52
399
1.39
1.24
1.5
1.7
1.5
1.0
mg/l
0.57
43
297
103
883
1.30
1.16
4.7
3.5
0.0
0.0
estimate
0.00
15
154
18
112
1.66
1.12
3.5
1.6
67.3
67.2
g/l
0.03
18
105
8
149
0.52
1.08
1.5
1.5
—
—
—
0
0
30
214
1.46
1.06
6.1
5.4
—
—
—
0
0
58
466
1.33
1.03
4.5
3.7
0.0
0.0
estimate
0.00
15
151
7
36
1.97
0.98
1.1
1.8
—
—
—
0
0
9
50
1.83
0.98
1.4
1.3
—
—
—
0
0
82
702
1.26
0.90
5.0
3.5
—
—
—
0
0
17
112
1.56
0.87
3.9
2.2
1.2
1.2
mmol/l
0.19
17
95
6
30
2.03
0.87
1.0
1.0
—
—
—
0
0
12
73
1.68
0.83
1.4
1.1
—
—
—
0
0
12
73
1.68
0.83
1.4
1.1
—
—
—
0
0
6
32
1.90
0.82
1.2
2.3
—
—
—
0
0
0
24
0.00
0.79
0.0
1.0
—
—
—
0
0
6
33
1.84
0.79
1.7
2.0
—
—
—
0
0
0
25
0.00
0.79
0.0
1.1
—
—
—
0
0
0
28
0.00
0.76
0.0
1.1
—
—
—
0
0
0
28
0.00
0.76
0.0
1.1
—
—
—
0
0
5
24
2.11
0.75
1.8
1.1
—
—
—
0
0
5
24
2.11
0.75
1.6
1.1
—
—
—
0
0
5
24
2.11
0.75
1.8
1.1
—
—
—
0
0
5
24
2.11
0.75
1.8
1.1
—
—
—
0
0
5
24
2.11
0.75
1.6
1.1
—
—
—
0
0
5
24
2.11
0.75
1.6
1.1
—
—
—
0
0
30
384
0.75
0.74
1.4
1.3
19.5
9.2
u/ml
0.36
12
148
51
425
1.26
0.70
2.6
2.2
3.5
3.0
mg/l
0.61
42
363
12
78
1.57
0.67
8.0
3.4
5.0
5.3
kpa
0.51
12
70
168
1766
0.82
0.62
4.5
5.1
1.8
2.5
mu/l
0.56
157
1649
70
613
1.20
0.60
3.0
3.3
29.1
26.6
ng/l
0.14
41
372
100
905
1.18
0.60
3.1
2.9
170.8
68.4
ug/l
2.01
94
846
8
52
1.56
0.60
2.1
1.5
—
—
—
0
0
7
113
0.61
0.59
1.0
1.0
—
—
—
0
0
20
150
1.36
0.58
1.8
1.7
—
—
—
0
0
17
124
1.40
0.57
2.1
1.9
62.0
70.5
ml/min/173m2
—
8
51
11
73
1.53
0.57
1.8
2.2
—
—
—
0
0
119
1283
0.85
0.57
3.0
3.4
—
—
—
0
0
20
151
1.36
0.56
1.8
1.7
—
—
—
0
0
9
60
1.52
0.55
2.3
1.8
—
—
—
0
0
10
67
1.51
0.50
1.6
2.3
1.8
1.0
%
—
10
67
24
190
1.29
0.50
15.2
17.1
0.9
1.2
inr
—
5
29
14
102
1.40
0.48
8.9
4.5
1.3
1.3
mmol/l
0.04
14
96
196
1895
1.22
0.48
26.8
11.5
75.1
69.1
umol/l
1.27
196
1895
32
377
0.82
0.42
1.4
1.3
13.0
36.0
iu/ml
—
10
124
0
15
0.00
0.41
0.0
1.6
—
—
—
0
0
0
17
0.00
0.41
0.0
1.0
—
1.1
—
0
9
8
60
1.35
0.40
1.1
1.3
240.4
57.7
pmol/l
—
8
60
10
71
1.43
0.40
9.3
4.6
24.9
25.0
mmol/l
—
10
71
9
69
1.32
0.37
2.9
2.5
41.3
40.9
u/l
—
9
64
16
126
1.29
0.36
1.3
1.3
—
—
—
0
0
10
73
1.39
0.35
1.3
1.8
—
—
—
0
0
35
400
0.85
0.34
1.2
1.6
—
—
—
0
0
7
52
1.36
0.31
1.7
1.8
—
232.0
—
0
5
45
403
1.14
0.31
2.7
2.2
318.9
4202.8
umol/l
1.55
37
353
147
1526
0.90
0.30
3.9
4.4
14.8
14.5
pmol/l
0.75
138
1414
35
311
1.15
0.27
3.1
3.5
598.2
310.5
ng/l
0.25
25
215
41
454
0.88
0.27
1.4
1.3
0.5
3.1
u/ml
1.47
14
137
173
1684
1.11
0.24
22.1
11.6
37.0
39.5
%
2.45
129
1277
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
36
395
0.90
0.21
1.6
1.5
16.5
22.2
nmol/l
2.34
31
341
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
9
114
0.78
0.20
2.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
10
122
0.81
0.19
1.6
1.4
—
—
—
0
0
121
1172
1.07
0.16
3.5
2.7
55.0
37.3
u/l
0.97
115
1101
194
1914
1.08
0.13
13.8
8.0
25.8
22.9
u/l
0.82
194
1842
33
307
1.09
0.13
1.6
1.6
938.7
1183.6
nmol/l
0.95
26
229
25
272
0.91
0.13
1.8
1.9
—
—
—
0
0
5
47
1.07
0.09
1.2
1.4
—
—
—
0
0
7
65
1.08
0.08
1.0
1.7
—
—
—
0
0
133
1350
0.97
0.07
4.0
4.0
16.5
11.0
mm/h
2.38
122
1247
20
207
0.96
0.01
1.4
1.6
—
—
—
0
0
24
241
1.00
0.00
1.8
1.8
—
—
—
0
0
69
692
1.00
0.00
2.0
2.0
83.6
98.7
pmol/l
1.93
47
345
12
116
1.04
0.00
10.2
3.0
107.3
76.7
ng/l
0.41
12
101
16
165
0.97
0.00
1.6
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
5
55
0.91
0.00
1.8
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
6.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
409.8
—
0
5
0
5
0.00
0.00
0.0
1.6
—
228.8
—
0
5
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
24.3
—
0
5
0
6
0.00
0.00
0.0
1.2
—
104.3
—
0
6
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
1928.2
—
0
6
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
5.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_CERVIX_SQUAM_EXALLC – Squamous cell neoplasms and carcinoma of cervix, excluding all cancers (controls excluding all cancers)
GWS hits: 1
This endpoint is excluded (different definition than used in FinnGen).